Prognostic importance of direct assignment of parent of origin via long-read genome and epigenome sequencing in retinoblastoma.
Andrew W Stacey, Kenji Nakamichi, Jennifer Huey...
https://pubmed.ncbi.nlm.nih.gov/39724000Actively Recruiting
Led by University of Washington · Updated on 2026-03-18
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
U
University of Washington
Lead Sponsor
N
National Eye Institute (NEI)
Collaborating Sponsor
Researchers are studying patients with ocular cancers and secondary cancers linked to mutations in the RB1 gene. This observational study aims to gain a detailed understanding of how genetic changes in RB1 relate to the development and spread of these cancers. By exploring the relationship between genetic information and disease traits, the study seeks to provide valuable insights into this cancer syndrome. All participants will undergo targeted long-read sequencing to analyze the genetic and epigenetic features of the RB1 gene. This advanced genetic testing helps to identify and understand the specific mutations involved. The study focuses on patients who have retinoblastoma caused by RB1 mutations or who show typical signs of retinoblastoma while awaiting genetic confirmation. Participants will provide consent and donate saliva or blood samples for genetic analysis. Researchers will perform detailed genetic and epigenetic profiling over a five-year period to understand the RB1 gene's role in these cancers. The study includes patients with various forms of retinoblastoma, including bilateral, unilateral, extraocular, and recurrent types, and involves no treatment interventions. Participants' involvement includes genetic testing and follow-up for outcome measurements.
CONDITIONS
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants undergo targeted long-read sequencing to analyze genomic and epigenomic signatures of the RB1 gene.
1 to 2 visits depending on genetic testing procedures
Duration - Up to 5 years
Participants are observed to correlate RB1 mutations with ocular tumors and metastasis over time.
Periodic visits during the 5-year follow-up
Total: 1 location
1
University of Washington
Seattle, Washington, United States, 98109
Actively Recruiting
D
Debarshi Mustafi, MD PhD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Andrew W Stacey, Kenji Nakamichi, Jennifer Huey...
https://pubmed.ncbi.nlm.nih.gov/39724000Kenji Nakamichi, Andrew Stacey, Debarshi Mustafi
https://pubmed.ncbi.nlm.nih.gov/36325802